Search

Olson, P., J. Lu, H. Zhang, A. Shai, M. G. Chun, Y. Wang, S. K. Libutti, E. K. Nakakura, T. R. Golub, and D. Hanahan. 2009. “MicroRNA Dynamics in the Stages of Tumorigenesis Correlate With Hallmark Capabilities of Cancer”. Genes Dev 23: 2152-65.

Parikh, A. R., I. Leshchiner, L. Elagina, L. Goyal, C. Levovitz, G. Siravegna, D. Livitz, et al. 2019. “Author Correction: Liquid versus Tissue Biopsy for Detecting Acquired Resistance and Tumor Heterogeneity in Gastrointestinal Cancers”. Nat Med 25: 1949.

Parsons, H. A., J. Rhoades, S. C. Reed, G. Gydush, P. Ram, P. Exman, K. Xiong, et al. 2020. “Sensitive Detection of Minimal Residual Disease in Patients Treated for Early-Stage Breast Cancer”. Clin Cancer Res 26: 2556-64.

Penney, K. L., J. A. Sinnott, K. Fall, Y. Pawitan, Y. Hoshida, P. Kraft, J. R. Stark, et al. 2011. “MRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer”. J Clin Oncol 29: 2391-6.

Perry, J. A., A. Kiezun, P. Tonzi, E. M. Van Allen, S. L. Carter, S. C. Baca, G. S. Cowley, et al. 2014. “Complementary Genomic Approaches Highlight the PI3K/MTOR Pathway As a Common Vulnerability in Osteosarcoma”. Proc Natl Acad Sci U S A 111: E5564-73.

Savage, K. J., S. Monti, J. L. Kutok, G. Cattoretti, D. Neuberg, L. Leval, P. Kurtin, et al. 2003. “The Molecular Signature of Mediastinal Large B-Cell Lymphoma Differs from That of Other Diffuse Large B-Cell Lymphomas and Shares Features With Classical Hodgkin Lymphoma”. Blood 102: 3871-9.

Sboner, A., F. Demichelis, S. Calza, Y. Pawitan, S. R. Setlur, Y. Hoshida, S. Perner, et al. 2010. “Molecular Sampling of Prostate Cancer: A Dilemma for Predicting Disease Progression”. BMC Med Genomics 3: 8.

Setlur, S. R., K. D. Mertz, Y. Hoshida, F. Demichelis, M. Lupien, S. Perner, A. Sboner, et al. 2008. “Estrogen-Dependent Signaling in a Molecularly Distinct Subclass of Aggressive Prostate Cancer”. J Natl Cancer Inst 100: 815-25.

Solit, D. B., L. A. Garraway, C. A. Pratilas, A. Sawai, G. Getz, A. Basso, Q. Ye, et al. 2006. “BRAF Mutation Predicts Sensitivity to MEK Inhibition”. Nature 439: 358-62.

Stathias, V., A. M. Jermakowicz, M. E. Maloof, M. Forlin, W. Walters, R. K. Suter, M. A. Durante, et al. 2018. “Drug and Disease Signature Integration Identifies Synergistic Combinations in Glioblastoma”. Nat Commun 9: 5315.